ARTICLE | Strategy
Borderless at Boehringer
Why Boehringer Ingelheim is doubling down on early stage research partnerships
July 14, 2016 7:00 AM UTC
With the launch of its new Innovation Unit on July 1, Boehringer Ingelheim GmbH is not only reorganizing its various research teams to streamline R&D, but is ramping up external partnerships to explore new biological concepts and technologies in anticipation of shifting market demands.
The company joins Sanofi and Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG, in announcing major restructuring of research this year, and all three are taking pains to emphasize that they are doubling down on external innovation...